Chemomab Therapeutics (CMMB) Non-Current Assets (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Non-Current Assets came in at $387000.0 in Q4 2025, down 58.12% YoY from $924000.0 in Q4 2024, and down 12.44% on a QoQ basis from $442000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) Non-Current Assets (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Non-Current Assets data on file, last reported at $387000.0 in Q4 2025.
- Quarterly Non-Current Assets fell 58.12% year-over-year to $387000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $387000.0 (down 58.12% YoY) and the FY2025 annual result came in at $387000.0, down 58.12% from the prior year.
- Non-Current Assets fell to $387000.0 in Q4 2025, from $442000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.7 million in Q2 2021 to a low of $387000.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 430.9% — and 2025, when it sank 58.12%.
- Tracing CMMB's Non-Current Assets over 5 years: stood at $1.7 million in 2021, then declined by 20.3% to $1.3 million in 2022, then declined by 5.5% to $1.3 million in 2023, then declined by 26.32% to $924000.0 in 2024, then slumped by 58.12% to $387000.0 in 2025.
- The last three Non-Current Assets figures came in at $387000.0 (Q4 2025), $442000.0 (Q3 2025), and $515000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 387,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 387,000.00 |
| Sep 30, 2025 | 442,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 842,000.00 |
| Dec 31, 2024 | 924,000.00 |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.55 Mn |
| Mar 31, 2022 | 1.62 Mn |
| Dec 31, 2021 | 1.67 Mn |
| Sep 30, 2021 | 1.60 Mn |
| Jun 30, 2021 | 1.68 Mn |
| Mar 31, 2021 | 600,000.00 |